Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity.

COVID-19 SARS-CoV-2 cell-free DNA disease severity liquid biopsy methylation tissue injury

Journal

Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215

Informations de publication

Date de publication:
09 04 2021
Historique:
received: 19 08 2020
revised: 16 11 2020
accepted: 06 01 2021
pubmed: 2 2 2021
medline: 2 2 2021
entrez: 1 2 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) primarily affects the lungs, but evidence of systemic disease with multi-organ involvement is emerging. Here, we developed a blood test to broadly quantify cell-, tissue-, and organ-specific injury due to COVID-19. Our test leverages genome-wide methylation profiling of circulating cell-free DNA in plasma. We assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls. We found evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. The concentration of cell-free DNA correlated with the World Health Organization (WHO) ordinal scale for disease progression and was significantly increased in patients requiring intubation. This study points to the utility of cell-free DNA as an analyte to monitor and study COVID-19. This work was supported by NIH grants 1DP2AI138242 (to I.D.V.), R01AI146165 (to I.D.V., M.P.C., F.M.M., and J.R.), 1R01AI151059 (to I.D.V.), K08-CA230156 (to W.G.), and R33-AI129455 to C.Y.C., a Synergy award from the Rainin Foundation (to I.D.V.), a SARS-CoV-2 seed grant at Cornell (to I.D.V.), a National Sciences and Engineering Research Council of Canada fellowship PGS-D3 (to A.P.C.), and a Burroughs-Wellcome CAMS Award (to W.G.). D.C.V. is supported by a Fonds de la Recherche en Sante du Quebec Clinical Research Scholar Junior 2 award. C.Y.C. is supported by the California Initiative to Advance Precision Medicine, and the Charles and Helen Schwab Foundation.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) primarily affects the lungs, but evidence of systemic disease with multi-organ involvement is emerging. Here, we developed a blood test to broadly quantify cell-, tissue-, and organ-specific injury due to COVID-19.
METHODS
Our test leverages genome-wide methylation profiling of circulating cell-free DNA in plasma. We assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls.
FINDINGS
We found evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. The concentration of cell-free DNA correlated with the World Health Organization (WHO) ordinal scale for disease progression and was significantly increased in patients requiring intubation.
CONCLUSIONS
This study points to the utility of cell-free DNA as an analyte to monitor and study COVID-19.
FUNDING
This work was supported by NIH grants 1DP2AI138242 (to I.D.V.), R01AI146165 (to I.D.V., M.P.C., F.M.M., and J.R.), 1R01AI151059 (to I.D.V.), K08-CA230156 (to W.G.), and R33-AI129455 to C.Y.C., a Synergy award from the Rainin Foundation (to I.D.V.), a SARS-CoV-2 seed grant at Cornell (to I.D.V.), a National Sciences and Engineering Research Council of Canada fellowship PGS-D3 (to A.P.C.), and a Burroughs-Wellcome CAMS Award (to W.G.). D.C.V. is supported by a Fonds de la Recherche en Sante du Quebec Clinical Research Scholar Junior 2 award. C.Y.C. is supported by the California Initiative to Advance Precision Medicine, and the Charles and Helen Schwab Foundation.

Identifiants

pubmed: 33521749
doi: 10.1016/j.medj.2021.01.001
pii: S2666-6340(21)00031-3
pmc: PMC7836424
doi:

Substances chimiques

Cell-Free Nucleic Acids 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Pagination

411-422.e5

Subventions

Organisme : NIAID NIH HHS
ID : DP2 AI138242
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI151059
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA230156
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI146165
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105704
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI129455
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH117406
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2021 Elsevier Inc.

Déclaration de conflit d'intérêts

A.P.C., M.P.C., W.G., C.Y.C., D.C.V., and I.D.V. are inventors on a patent application submitted by Cornell University Center for Technology Licensing.

Auteurs

Alexandre Pellan Cheng (AP)

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.

Matthew Pellan Cheng (MP)

McGill University Health Center, Montreal, QC, Canada.

Wei Gu (W)

Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Department of Pathology, Stanford University, Stanford, CA, USA.

Joan Sesing Lenz (J)

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.

Elaine Hsu (E)

Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.

Erwin Schurr (E)

Department of Human Genetics, McGill University, Montreal, QC, Canada.

Guillaume Bourque (G)

Department of Human Genetics, McGill University, Montreal, QC, Canada.
Canadian Centre for Computational Genomics, Montreal, QC, Canada.

Mathieu Bourgey (M)

Department of Human Genetics, McGill University, Montreal, QC, Canada.
Canadian Centre for Computational Genomics, Montreal, QC, Canada.

Jerome Ritz (J)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Francisco M Marty (FM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA.

Charles Y Chiu (CY)

Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA.

Donald C Vinh (DC)

McGill University Health Center, Montreal, QC, Canada.

Iwijn De Vlaminck (I)

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH